In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.

However, the rebate game played by drug manufacturers and pharmacy benefit managers in the U.S. limits optimal biosimilar competition. As a result, U.S. patient out-of-pocket costs are too high.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...